Metagenomi (NASDAQ:MGX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%.
Metagenomi Stock Performance
Shares of NASDAQ MGX traded down $0.06 during midday trading on Monday, reaching $1.88. 440,558 shares of the company were exchanged, compared to its average volume of 728,899. The stock’s 50-day moving average price is $2.52 and its 200-day moving average price is $2.52. Metagenomi has a one year low of $1.61 and a one year high of $11.86.
Institutional Trading of Metagenomi
A hedge fund recently raised its stake in Metagenomi stock. Bank of America Corp DE boosted its position in Metagenomi, Inc. (NASDAQ:MGX – Free Report) by 482.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,113 shares of the company’s stock after buying an additional 17,491 shares during the period. Bank of America Corp DE owned approximately 0.06% of Metagenomi worth $76,000 at the end of the most recent quarter.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on Metagenomi
About Metagenomi
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Featured Articles
- Five stocks we like better than Metagenomi
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Can TikTok Stock Picks Really Make You Rich?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- The “Quality” Rotation: Back to Basics Investing
- How to Choose Top Rated Stocks
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.